NASDAQ:MCRBSeres Therapeutics Stock Price, Forecast & News

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MCRB stock has increased by 89.0% and is now trading at $4.99. View which stocks have been most impacted by Coronavirus.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Seres Therapeutics.

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Seres Therapeutics.

Seres Therapeutics Inc (NASDAQ:MCRB) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.28). The biotechnology company had revenue of $8.19 million for the quarter, compared to the consensus estimate of $8.01 million. View Seres Therapeutics' earnings history.

5 brokerages have issued 1 year price targets for Seres Therapeutics' stock. Their forecasts range from $7.00 to $12.50. On average, they anticipate Seres Therapeutics' share price to reach $9.63 in the next year. This suggests a possible upside of 92.9% from the stock's current price. View analysts' price targets for Seres Therapeutics.

Media headlines about MCRB stock have trended somewhat negative recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seres Therapeutics earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news about Seres Therapeutics.

Seres Therapeutics saw a increase in short interest in the month of June. As of June 15th, there was short interest totaling 6,740,000 shares, an increase of 8.7% from the May 31st total of 6,200,000 shares. Based on an average trading volume of 399,700 shares, the days-to-cover ratio is presently 16.9 days. Approximately 15.7% of the shares of the company are sold short. View Seres Therapeutics' Current Options Chain.

Some companies that are related to Seres Therapeutics include Karyopharm Therapeutics (KPTI), Revance Therapeutics (RVNC), Akcea Therapeutics (AKCA), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Kiniksa Pharmaceuticals (KNSA), Heron Therapeutics (HRTX), Esperion Therapeutics (ESPR), Odonate Therapeutics (ODT), Amneal Pharmaceuticals (AMRX), Tricida (TCDA), Arvinas (ARVN), Theravance Biopharma (TBPH) and Rocket Pharmaceuticals (RCKT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include Opko Health (OPK), TherapeuticsMD (TXMD), Juno Therapeutics (JUNO), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Novavax (NVAX), BioCryst Pharmaceuticals (BCRX), Exelixis (EXEL) and Gilead Sciences (GILD).

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MCRB stock can currently be purchased for approximately $4.99.

Seres Therapeutics has a market capitalization of $362.27 million and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis. Seres Therapeutics employs 145 workers across the globe.

The official website for Seres Therapeutics is www.serestherapeutics.com.

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]